US REGULATORY RECORDS
- FDA API DMF records
- 6
- Active (A)
- 4
- Inactive (I)
- 2
FDA list cutoff:
ACTIVE PHARMACEUTICAL INGREDIENT
Research Azithromycin API through FDA DMF and China CDE records. Compare reported holders, registration numbers and status definitions, then subscribe to search and export complete available data.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
The chemical profile identifies the parent compound, CAS 83905-01-5. Records are selected by reported name; an unspecified hydration state does not establish anhydrous material. Explicit hydrates, salts, finished dosage forms and intermediates are excluded. Unresolved N and FORM I subjects are also excluded.
This overview includes 6 FDA API DMF records and 33 CDE API registrations for Azithromycin (CAS 83905-01-5), selected by reported substance name. FDA and CDE status counts follow each registry’s own definitions.
FDA list cutoff:
CDE export captured:
0 documented company-name correspondences
The registries have different snapshot dates. Record counts do not represent qualified or available suppliers. Azithromycin records without a stated hydration state do not establish anhydrous material. A lack of documented company-name correspondences does not establish that no companies appear in both registries.
$19.00 per month
$149.00 per year
Billed $149.00 every year
This profile: 6 FDA DMF records, 33 CDE registrations and 0 company-name correspondences.
One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.
Start an Azithromycin supplier search with the reported names in each market. No cross-registry company-name correspondences are documented for this profile. Similar names, translations and membership of the same corporate group do not prove an identical legal entity or manufacturing site.
Free previewShowing 0 sample records of 0.
0 company-name correspondences
No exact company-name correspondences are documented for these snapshots.
Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.
Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.
US REGULATORY RECORDS
Compare the original Azithromycin subjects, holder names, submission dates and activity status. The selection includes an explicit anhydrous subject and API subjects without a stated hydration state; consult the holder for the actual material form.
4Active (A)
2Inactive (I)
A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.
Free previewShowing 3 sample records of 6.
Free preview
More records available with a subscription: 3.
CHINA REGULATORY RECORDS
Compare Azithromycin API registrations reported as 阿奇霉素, including original company names, addresses, packaging and joint-review identifiers. The reported substance name does not specify hydration state.
30Approved or qualifying prior approval (A)
3Technical review not passed or unlinked (I)
CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.
Free previewShowing 3 sample records of 33.
Free preview
More records available with a subscription: 30.
Azithromycin is a macrolide antibiotic identified here by CAS 83905-01-5 and ChEBI CHEBI:2955. The formula and structure describe the parent molecule without water of crystallization. USP distinguishes anhydrous, monohydrate and dihydrate forms. A registry subject that simply says Azithromycin does not verify the physical form supplied by a manufacturer.
Parent compound identity; not a CAS assignment verified individually for every registry record.
Use these parent-compound identifiers to compare chemical references. Azithromycin monohydrate and dihydrate have separate CAS numbers and contain one and two waters of crystallization respectively. Confirm hydration state, assay basis and the applicable specification with the manufacturer before comparing materials.
Average mass reported by ChEBI for the parent compound; not a batch assay or specification.
Use these official Azithromycin references to check substance identity and interpret the scope of the registration records.
Compare the formula and stereochemical structure for Azithromycin, CAS 83905-01-5.
Check the separate CAS numbers for Azithromycin, its monohydrate and its dihydrate before comparing materials.
Understand why an active Azithromycin DMF does not mean FDA approval of a product or supplier.
Check current Azithromycin entries and their reported company, packaging and joint-review information.
The chemical profile covers Azithromycin, CAS 83905-01-5, with molecular formula C38H72N2O12. Its structure represents the parent compound. Registration tables are selected by reported substance names, so they do not confirm that every listed material is anhydrous.
Azithromycin monohydrate has CAS 121470-24-4 and contains one water of crystallization; the dihydrate has CAS 117772-70-0 and contains two. The anhydrous identity has CAS 83905-01-5. USP describes all three forms in its monograph preview, so a USP subject alone does not identify hydration state. Explicit hydrate subjects are excluded here.
The FDA snapshot contains 6 Type II Azithromycin API records selected from unqualified, USP, USP (API), anhydrous and lyophilized bulk sterile subjects. Type II also covers intermediates and drug products, so the type alone is insufficient. Explicit hydrates, salts, facilities, granules and an amine intermediate are excluded.
DMF 15985 reports AZITHROMYCIN N and DMF 16268 reports AZITHROMYCIN-FORM I. The supplied list does not resolve their chemical identities or hydration states. They are excluded pending substance-level evidence rather than assigned to CAS 83905-01-5. These qualifiers are not treated as verified synonyms of the parent compound.
No. A and I indicate active and inactive DMFs. FDA states that DMFs are neither approved nor disapproved; technical contents are reviewed with applications that reference them. An Azithromycin DMF number does not establish manufacturing-site qualification, access to a dossier, current supply or suitability for a particular application.
For these Azithromycin registrations, A and I describe Chinese review status independently of FDA activity. A can result from joint review with an approved formulation, transfer of qualifying prior approvals or an independent API review. I identifies material that has not passed technical review or has not been linked to a formulation registration. Check the current official entry before relying on its status.
The CDE selection contains 33 records named exactly 阿奇霉素. Related salt forms have different substance names and are excluded from this Azithromycin parent-compound profile. The Chinese name alone does not verify water content, a particular crystalline form or a manufacturer specification.
Use the registry number to locate the original entry, then ask the company to confirm its legal name, manufacturing site, chemical form, specification and applicable regulatory documentation. A CDE company field can list multiple parties. This page does not infer their roles from order or equate translated names with an FDA holder.
Review free Azithromycin samples and download their sample CSV files before subscribing. An active personal subscription provides the complete available records for this profile, with search, status filters and CSV exports. It does not provide quotations, supplier qualification or live registry monitoring.
Official references for chemical identity, registration records and status definitions. Open the original source to check current information.
EMBL-EBI
Parent-compound CAS, molecular formula, calculated masses, InChIKey and stereochemical SMILES.
“C38H72N2O12”
EMBL-EBI
Molecular formula reported in the ChEBI entry CHEBI:2955.
United States Pharmacopeia
The public monograph preview distinguishes anhydrous, monohydrate and dihydrate identities. It is used for chemical-form identification, not as a current batch specification.
“Azithromycin is anhydrous or contains 1 or 2 molecules of water of hydration.”
United States Pharmacopeia
Definition in the USP-NF Azithromycin monograph preview, cited there as 2023; the preview is not evidence that a listed material meets a current monograph.
U.S. Food and Drug Administration
The records displayed here use the second-quarter snapshot, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.
“A=active ; I=inactive”
U.S. Food and Drug Administration
FDA activity-status legend; the snapshot date applies to the records shown here.
U.S. Food and Drug Administration
FDA explains how DMFs support applications that reference their technical contents.
“Are neither approved nor disapproved.”
U.S. Food and Drug Administration
FDA statement about DMFs; active status is not product approval.
U.S. Food and Drug Administration
Type II covers drug substances, intermediates, preparation materials and drug products; a subject-level screen is needed to select API records.
“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”
U.S. Food and Drug Administration
FDA definition of Type II; the category is broader than API-only filings.
Center for Drug Evaluation, National Medical Products Administration
The October 5, 2026 snapshot contains the reported names, company fields and registration information used here.
“阿奇霉素”
Center for Drug Evaluation, National Medical Products Administration
Original substance name in the CDE snapshot; the name alone does not specify hydration state.
Liaoning Medical Products Administration
Official explanation of the A and I identifiers, including the different routes by which a record can receive A status.
“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”
Liaoning Medical Products Administration
The regulator explains I as material that has not passed technical review or has not been linked to a formulation registration.
Compare Azithromycin registry names, statuses and chemical-form boundaries using the free samples. Subscribe to search, filter and export the complete available FDA and CDE records for your sourcing review.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
Report an Azithromycin data issue with the page address, registry number and supporting official source. APIRFQ support handles data corrections; contact the relevant company separately about material specifications or supply.
Contact data support